GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (NAS:XERS) » Definitions » Current Ratio

Xeris Biopharma Holdings (Xeris Biopharma Holdings) Current Ratio : 1.64 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Xeris Biopharma Holdings's current ratio for the quarter that ended in Dec. 2023 was 1.64.

Xeris Biopharma Holdings has a current ratio of 1.64. It generally indicates good short-term financial strength.

The historical rank and industry rank for Xeris Biopharma Holdings's Current Ratio or its related term are showing as below:

XERS' s Current Ratio Range Over the Past 10 Years
Min: 1.64   Med: 4.3   Max: 13.13
Current: 1.64

During the past 8 years, Xeris Biopharma Holdings's highest Current Ratio was 13.13. The lowest was 1.64. And the median was 4.30.

XERS's Current Ratio is ranked worse than
72.54% of 1555 companies
in the Biotechnology industry
Industry Median: 3.71 vs XERS: 1.64

Xeris Biopharma Holdings Current Ratio Historical Data

The historical data trend for Xeris Biopharma Holdings's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Current Ratio Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 3.20 5.40 1.80 2.54 1.64

Xeris Biopharma Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.54 2.03 1.95 1.82 1.64

Competitive Comparison of Xeris Biopharma Holdings's Current Ratio

For the Biotechnology subindustry, Xeris Biopharma Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xeris Biopharma Holdings's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Current Ratio distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's Current Ratio falls into.



Xeris Biopharma Holdings Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Xeris Biopharma Holdings's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=156.264/95.193
=1.64

Xeris Biopharma Holdings's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=156.264/95.193
=1.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xeris Biopharma Holdings  (NAS:XERS) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Xeris Biopharma Holdings Current Ratio Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xeris Biopharma Holdings (Xeris Biopharma Holdings) Business Description

Traded in Other Exchanges
Address
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Executives
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Steven Pieper officer: Chief Financial Officer XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Dawn Halkuff director C/O XERIS PHARMACEUTICALS, 180 N. LASALLE ST., STE. 1800, CHICAGO IL 60601
Shannon John Patrick Jr officer: See Remarks DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Paul R Edick director, officer: See Remarks C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Ricki Louise Fairley director XERIS BIOPHARMA HOLDINGS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Steven Prestrelski officer: Chief Scientific Officer C/O XERIS PHARMACEUTICALS, 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Beth Hecht officer: See Remarks C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Kenneth Erland Johnson officer: See Remarks C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Barbara-jean Anne Bormann-kennedy director 1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Marla Persky director ONE BAXTER PARKWAY, DEERFIELD IL 60015
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong director 712 COLLEGE AVENUE, MENLO PARK CA 94025
Barry M. Deutsch officer: See Remarks OVATION PHARMACEUTICALS, INC. FOUR PARKWAY NORTH, SUITE 200 DEERFIELD IL 60015